NASDAQ: ENTXEntera Bio Ltd Stock
$1.79+0.03 (+1.7%)
Updated Apr 17, 2025
ENTX Price
$1.79
Fair Value Price
$0.21
Market Cap
$81.30M
52 Week Low
$1.41
52 Week High
$2.79
P/E
-7.16x
P/B
10.06x
P/S
440.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$181.00k
Earnings
-$9.54M
Gross Margin
5%
Operating Margin
-5,263.54%
Profit Margin
-5,271.3%
Debt to Equity
0.16
Operating Cash Flow
-$7M
Beta
0.53
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ENTX Overview
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENTX's potential to beat the market
- ENTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENTX
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important ENTX news, forecast changes, insider trades & much more!
ENTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENTX ($1.79) is overvalued by 737.95% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ENTX ($1.79) is not significantly undervalued (737.95%) relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ENTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENTX due diligence checks available for Premium users.
Valuation
ENTX fair value
Fair Value of ENTX stock based on Discounted Cash Flow (DCF)
Price
$1.79
Fair Value
$0.21
Overvalued by
737.95%
ENTX ($1.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENTX ($1.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.16x
Industry
-177.72x
Market
27.98x
ENTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.06x
Industry
4.05x
ENTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENTX's financial health
Profit margin
Revenue
$82.0k
Net Income
-$2.4M
Profit Margin
-2,875.6%
ENTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ENTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$1.3M
Debt to equity
0.16
ENTX's short-term assets ($8.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENTX's short-term assets ($8.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
-$3.0k
Financing
$3.2M
ENTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENTX vs Biotech Stocks
Entera Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.